Spyre Therapeutics (SYRE) Operating Leases (2019 - 2023)
Spyre Therapeutics (SYRE) posted Operating Leases of $3.8 million for Q1 2023, down 4.52% on a QoQ basis from $4.0 million in Q4 2022, and down 14.42% year-over-year from $4.5 million in Q1 2022.
Spyre Therapeutics (SYRE) Operating Leases (2019 - 2023) Analysis & Trends
Spyre Therapeutics' Operating Leases history runs 5 years deep, the most recent figure standing at $3.8 million for Q1 2023.
- Quarterly Operating Leases fell 14.42% year-over-year to $3.8 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $3.8 million (down 14.42% YoY) and the FY2022 annual result came in at $4.0 million, down 13.11% from the prior year.
- Operating Leases was $3.8 million for Q1 2023 at Spyre Therapeutics, down from $4.0 million in the prior quarter.
- Across five years, Operating Leases topped out at $5.1 million in Q4 2020 and bottomed at $372000.0 in Q1 2019.
- A 5-year average of $4.4 million and a median of $4.7 million in 2019 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2020 — Operating Leases soared 1194.35% — and 2023, when it dropped 14.42%.
- Spyre Therapeutics' Operating Leases stood at $4.7 million in 2019, then grew by 8.85% to $5.1 million in 2020, then declined by 10.16% to $4.6 million in 2021, then fell by 13.11% to $4.0 million in 2022, then decreased by 4.52% to $3.8 million in 2023.
- Business Quant data shows SYRE's Operating Leases at $3.8 million in Q1 2023, $4.0 million in Q4 2022, and $4.2 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 3.82 Mn |
| Dec 31, 2022 | 4.00 Mn |
| Sep 30, 2022 | 4.16 Mn |
| Jun 30, 2022 | 4.32 Mn |
| Mar 31, 2022 | 4.47 Mn |
| Dec 31, 2021 | 4.61 Mn |
| Sep 30, 2021 | 4.75 Mn |
| Jun 30, 2021 | 4.88 Mn |
| Mar 31, 2021 | 5.01 Mn |
| Dec 31, 2020 | 5.13 Mn |
| Sep 30, 2020 | 4.95 Mn |
| Jun 30, 2020 | 4.70 Mn |
| Mar 31, 2020 | 4.82 Mn |
| Dec 31, 2019 | 4.71 Mn |
| Sep 30, 2019 | 4.87 Mn |
| Jun 30, 2019 | 4.82 Mn |
| Mar 31, 2019 | 372,000.00 |